ѧÊõÌÃÊ×Ò³ | ÎÄÏ×ÇóÖúÂÛÎÄ·¶ÎÄ | ÂÛÎÄÌâÄ¿ | ²Î¿¼ÎÄÏ× | ¿ªÌⱨ¸æ | ÂÛÎĸñʽ | ÕªÒªÌá¸Ù | ÂÛÎÄÖÂл | ÂÛÎIJéÖØ | ÂÛÎÄ´ð±ç | ÂÛÎÄ·¢±í | ÆÚ¿¯ÔÓÖ¾ | ÂÛÎÄд×÷ | ÂÛÎÄPPT
ѧÊõÌÃרҵÂÛÎÄѧϰƽ̨Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ҽѧÂÛÎÄ > »ù´¡Ò½Ñ§ÂÛÎÄ > ´«È¾²¡Ñ§ÂÛÎÄ

²¡¶¾ÐÔƤ·ô²¡Ê¹ÓÃðà¿Ë¾»µÄÁÆЧ·ÖÎö

À´Ô´£ºÊýÀíҽҩѧÔÓÖ¾ ×÷Õߣº±ßéª
·¢²¼ÓÚ£º2021-11-16 ¹²2935×Ö

¡¡¡¡Õª    Òª£º¡¡Ä¿µÄ£ºÌ½¾¿ÖÎÁƲ¡¶¾ÐÔƤ·ô²¡Ñ¡ÓÃðà¿Ë¾»µÄЧ¹û¡£·½·¨£ºÑ¡È¡Ä³ÔºÃÅÕï2018Äê8Ô¡«2019Äê8ÔÂÆÚ¼äÊÕÖεÄ66Àý²¡¶¾ÐÔƤ·ô²¡»¼ÕßΪÑù±¾£¬Í¨¹ý¼ÆËã»úËæ»ú·¨½«66Àý»¼Õß·ÖΪʵÑé×é(Î÷ßäÌ涡)ºÍ¶ÔÕÕ×é(Î÷ßäÌ涡ÁªºÏðà¿Ë¾»)¸÷33Àý£¬¶Ô±ÈÁ½×éÖÎÁÆЧ¹ûÓë²»Á¼·´Ó¦Çé¿ö¡£½á¹û£ºÊµÑé×é96.97%µÄ×ÜÓÐЧÂʽ϶ÔÕÕ×é72.73%µÄ×ÜÓÐЧÂʸß(P<0.05);ʵÑé×é15.15%µÄ²»Á¼·´Ó¦·¢ÉúÂÊÓë¶ÔÕÕ×é9.09%µÄ·¢ÉúÂÊÏà±È²îÒì²»´ó(P>0.05)¡£½áÂÛ£ºÓ¦ÓÃðà¿Ë¾»¾ßÓÐÒ»¶¨°²È«ÐÔ£¬ÇÒЧ¹ûÏÔ×Å£¬ÁÙ´²ÖÎÁÆ¿ÉÑ¡Óá£

¡¡¡¡¹Ø¼ü´Ê :     ðà¿Ë¾»;²¡¶¾ÐÔƤ·ô²¡;ÖÎÁÆЧ¹û;²»Á¼·´Ó¦;

¡¡¡¡Abstract£º¡¡Objective: To explore the effect of Youkejing in the treatment of viral skin diseases.Methods:66 patients with viral skin diseases treated in a hospital from August 2018 to August 2019 were selected and divided into experimental group(n=33, cimetidine) and control group(n=33, cimetidine combined with Youkejing) by computer randomization.The therapeutic effect and adverse reactions of two groups were compared.Results: The total effective rate of in the experimental group was 96.97%,which was higher than 72.73% in the control group(P<0.05). The incidence of adverse reactions in the experimental group was 15.15%,which did not differ significantly from 9.09% in the control group(P>0.05).Conclusion: The application of Youkejing is safe and effective, which can be selected in the clinical treatment.

¡¡¡¡Keyword£º¡¡Youkejing; viral skin diseases; therapeutic effect; adverse reactions;

¡¡¡¡²¡¶¾ÐÔƤ·ô²¡ÊÇƤ·ô¿Æ³£¼û²¡Ö¢£¬¸ÐȾ²¡¶¾ÊÇÆä·¢²¡»úÖÆ£¬²¡¶¾ÇÖÏ®ÈËÀà»úÌåÆÆ»µÆ¤·ô×éÖ¯¡¢Éñ¾­×éÖ¯£¬Æ«ÓÚÉñ¾­Õß¿É·¢ÉúðåÕîÀàƤ·ô²¡£¬Æ«ÓÚƤ·ô×éÖ¯Õß¿É·¢ÉúðàÀàƤ·ô²¡[1]¡£ÖÎÁƲ»¼°Ê±»òÕßÖÎÁƲ»µ±¶Ô»¼ÕßÉú»îÖÊÁ¿¡¢ÐÄÀí×´¿ö¾ù»á²úÉú½Ï´ó²»Á¼Ó°Ïì¡£ÁÙ´²±íÏÖ°üÀ¨Æ¤·ô´ÌÍ´¡¢¾Ö²¿×ÆÉÕ¡¢Éñ¾­ÐÔÌÛÍ´µÈ£¬Èô²¡ÇéÊ®·ÖÑÏÖØ»¹¿ÉÄÜ·¢Éú¸ÐȾ£¬µ¼Ö»¼Õß·¢ÈÈ£¬²¡ÇéǨÑÓ²»Óú¡£Òò´Ë£¬¼°ÔçÖÎÁƶÔÆäÓÈΪÖØÒª£¬ÁÙ´²ÒÔÒ©ÎïÖÎÁÆΪÖ÷£¬Î÷ßäÌ涡Ч¹ûÁ¼ºÃ¡£±¾ÊÀ¼Í³õ£¬ÁÙ´²ÊµÑé±íʾðà¿Ë¾»Ó¦ÓÃÓÚCAÖÎÁÆЧ¹ûÏÔ×Å£¬ÎªÁË̽¾¿¸ÃÒ©ÎﰲȫÐÔÓëÓÐЧÐÔ£¬±¾Ñо¿ÔÚÎ÷ßäÌ涡µÄ»ù´¡ÉÏÓ¦ÓÃðà¿Ë¾»½øÐÐÖÎÁÆ£¬Ñ¡È¡Ä³ÔºÆ¤·ô¿Æ2018Äê8Ô¡«2019Äê8ÔÂÆÚ¼äÊÕÖεÄ66Àý²¡¶¾ÐÔƤ·ô²¡»¼ÕßΪÑù±¾£¬ÏÖ±¨µÀÈçÏ¡£

¡¡¡¡1 ¡¢×ÊÁϼ°·½·¨

¡¡¡¡1.1¡¢ Ò»°ã×ÊÁÏ

¡¡¡¡Ñ¡È¡Ä³ÔºÆ¤·ô¿Æ2018Äê8Ô¡«2019Äê8ÔÂÆÚ¼äÊÕÖεÄ66Àý²¡¶¾ÐÔƤ·ô²¡»¼ÕßΪÑù±¾¡£Í¨¹ý¼ÆËã»úËæ»ú·¨½«66Àý»¼Õß·ÖΪʵÑé×éºÍ¶ÔÕÕ×é¸÷33Àý¡£ÊµÑé×éÄÐ18Àý(54.55%),Å®15Àý(45.45%);ÄêÁä18¡«46Ë꣬ƽ¾ùÄêÁä(32.11¡À6.23)Ëꣻ²¡³Ì6d¡«1.5Äꣻƽ¾ù²¡³Ì(54.28¡À10.47)d; Ƥ·ô²¡ÀàÐÍ£º¼âÈñʪðà(CA)21Àý(%),´ø×´ðåÕî9Àý(27.27%),ÉúÖ³Æ÷ðåÕî3Àý(9.09%)¡£¶ÔÕÕ×éÄÐ20Àý(60.61%),Å®13Àý(39.39%);ÄêÁä19¡«48Ë꣬ƽ¾ùÄêÁä(33.01¡À6.04)Ëꣻ²¡³Ì5d¡«1.5Äꣻƽ¾ù²¡³Ì(50.17¡À11.22)d; Ƥ·ô²¡ÀàÐÍ£º¼âÈñʪðà20Àý(60.61%),´ø×´ðåÕî10Àý(30.30%),ÉúÖ³Æ÷ðåÕî3Àý(9.09%)¡£Á½×é×ÊÁϲîÒìÐÔ²»ÏÔ×Å(P>0.05),¿É½øÐжԱȡ£

¡¡¡¡1.2¡¢ ·½·¨

¡¡¡¡Á½×é¾ù½ÓÊÜ7¡«14dµÄÖÎÁÆ¡£

¡¡¡¡¶ÔÕÕ×é²ÉÓÃÎ÷ßäÌ涡(¹úÒ©×¼×ÖH31020484)¡£¹æ¸ñ£º0.2g*100Ƭ¡£³§¼Ò£ºÉϺ£ÐÅÒêÌìƽҩҵÓÐÏÞ¹«Ë¾¡£Ó÷¨ÓÃÁ¿£º¿Ú·þÓÃÒ©0.6g/´Î£¬1´Î/d¡£

¡¡¡¡ÊµÑé×éʹÓÃÎ÷ßäÌ涡(Óë¶ÔÕÕ×éÏàͬ)ÁªºÏðà¿Ë¾»£¬ðà¿Ë¾»»ù±¾Ó÷¨£ºµãÍ¿£¬2´Î/d, ³ÖÐøʹÓÃ3d¡£¾ßÌåÈçÏ£º(1)¼âÈñʪðࣺÈô´øµÙÆ«´óÔò½«Ò©ÒºµãÓÚ»ùµ×²¿Î»ÓëµÙ²¿¡£ðàÌåÍÑÂäÖ®ºóÔÙ´ÎͿĨÓÚ»ùµ×²¿Î»¼°ÆäÖÜΧ0.2cm×óÓÒ£¬¸ü¸ÄΪ1´Î/d; (2)´ø×´ðåÕîÓëÉúÖ³Æ÷ðåÕµãͿƤËð²¿Î»2´Î/d, ƤËð¸ÉÔïºó¸ü¸ÄΪ1´Î/d¡£

1.png

¡¡¡¡1.3 ¡¢¹Û²ìÖ¸±ê

¡¡¡¡ÖÎÁÆЧ¹ûÓë²»Á¼·´Ó¦Çé¿ö¡£

¡¡¡¡1.4 ¡¢ÁÆЧÅж¨

¡¡¡¡ÖÎÁÆЧ¹û£ºÏÔЧ£ºðàÌåÓëƤËðºÃת¶È>70%;ÓÐЧ£ºðàÌåÓëƤËðÓÐËùºÃת£¬ºÃת¶È¡Ü70%;ÎÞЧ£ºðàÌåÓëƤËðûÓиÄÉÆ£¬¸Ä±äÖÎÁÆ·½·¨£¬»òÕßÖÎÓúºóÍ£Ò©7dÄÚ¸´·¢¡£×ÜÓÐЧ=(ÏÔЧ+ÓÐЧ)/ÀýÊý¡Á100%¡£

¡¡¡¡²»Á¼·´Ó¦Çé¿ö£º¹Û²ìÓë¼Ç¼Á½×éÖÎÁÆÆÚ¼äË®Öס¢ÃÓÀᢺì°ß¡¢À£ÑñÒÔ¼°ÌÛÍ´5ÖÖ²»Á¼·´Ó¦£¬Ô½ÉÙÔ½ºÃ¡£

¡¡¡¡1.5¡¢ ͳ¼Æѧ´¦Àí

¡¡¡¡²ÉÓÃSPSS21.0ͳ¼ÆѧÈí¼þ½øÐÐÊý¾Ý·ÖÎö£¬ÓëÖÎÁÆЧ¹û¡¢À£Ññ¡¢Ë®Ö׵Ȳ»Á¼·´Ó¦ÀàËƵļÆÊý×ÊÁϾù²ÉÓÃ[n(%)]±íʾ£¬ÐЦÖ2¼ìÑé¡£P<0.05±íʾ²îÒìÓÐͳ¼ÆѧÒâÒå¡£

¡¡¡¡2 ¡¢½á¹û

¡¡¡¡2.1¡¢ ÖÎÁÆЧ¹û

¡¡¡¡ÊµÑé×é96.97%µÄ×ÜÓÐЧÂʽ϶ÔÕÕ×é72.73%µÄ×ÜÓÐЧÂʸß(P<0.05),¼û±í1¡£

¡¡¡¡±í1 Á½×éÖÎÁÆЧ¹û±È½Ï[n(%)]

1`.png

¡¡¡¡2.2¡¢ ²»Á¼·´Ó¦Çé¿ö

¡¡¡¡ÊµÑé×é15.15%µÄ²»Á¼·´Ó¦·¢ÉúÂÊÓë¶ÔÕÕ×é9.09%µÄ·¢ÉúÂÊÏà±È²îÒì²»´ó(P>0.05),¼û±í2¡£

¡¡¡¡±í2 Á½×é²»Á¼·´Ó¦Çé¿ö[n(%)]

2.png

¡¡¡¡3¡¢ ÌÖÂÛ

¡¡¡¡¼°ÔçÖÎÁƲ¡¶¾ÐÔƤ·ô²¡ÓÐÀûÓÚ»¼Õ߸ÄÉÆÉú»îÖÊÁ¿£¬¶Ô»¼Õß±£ÕϽ¡¿µ¾ßÓÐÖØÒªÒâÒ塣Ŀǰ£¬ÁÙ´²´æÔÚ¶àÖÖÓÃÓÚÖÎÁƸü²²¡µÄÒ©Îµ«Ò©ÎïÐÔÖÊ¡¢Å¨¶È¡¢¹¦Äܵȸ÷ÓÐÆ«ÖØ£¬Ñ¡Ôñ×î¼ÑÒ©ÎïÖÁ¹ØÖØÒª¡£Î÷ßäÌ涡ÁÙ´²Ó¦ÓÃÂʸߣ¬Æä¾ßÓа²È«¡¢¾­¼Ã¡¢²»Á¼·´Ó¦ÉÙµÈÓ¦ÓÃÓÅÊÆ£¬Æäͨ¹ý×è¶ÏH2ÊÜÌåµÄ·½·¨ÒÖÖÆθËá·ÖÃÚ£¬Í¬Ê±ÁªºÏH1ÊÜÌå·¢»ÓÞ׿¹¼ÁЧ¹û£¬¿ÉÒÔÓÃÓÚÖÎÁƲ¡¶¾ÐÔƤ·ô²¡[2]¡£

¡¡¡¡ðà¿Ë¾»ÊôÓÚ´¿ÖÐÒ©ÖƼÁ£¬ÊÇÀ¥Ã÷»ª¶¼ÖÆÒ©ÓÐÏÞ¹«Ë¾³öÆ·µÄÍⲿͿĨҩÎï¡£¾­¹ýÁÙ´²ÊÔÑ飬½á¹û±íʾðà¿Ë¾»¾ßÓÐÏÔ×ŵĿ¹Ñ×Ч¹û£¬Äܹ»Ã÷ÏÔÒÖÖÆס´óÊóÇíÖ¬¾Ö²¿Æ¤ÏÂË®Ö×µÄÎÊÌ⣬ͬʱ¿É·À·¶ÔöÉú¡£ÇÒÁÙ´²ÊÔÑéÒ²±íʾ£¬ðà¿Ë¾»¶ÔƤ·ôûÓд̼¤×÷Óã¬Ò²ÎÞ¹ýÃôÎÊÌ⣬³¤ÆÚʹÓÃЧ¹ûÁ¼ºÃ£¬ÎÞ¶¾¸±×÷Óá£Í¨¹ý´óÊóÒõµÀ¡¢Òõ¾¥µãÍ¿ÖÎÁÆÒ²·¢ÏÖÎÞ¶¾¸±×÷ÓÃÒÔ¼°´Ì¼¤·´Ó¦¡£µ¥´¿ÔÚÒõµÀµãÍ¿Ò©Î¾­Óɲ¡Àí¼ì²é·¢ÏÖ¶ÔÆäÓÐÇá΢´Ì¼¤ÐÔ£¬Í£Ö¹ÓÃÒ©ºó¼´¿É»Ö¸´¡£Òò´Ë£¬ðà¿Ë¾»°²È«¡¢ÎÞ¶¾¡¢Ó¦Óüò±ã¡¢Ð§¹ûÏÔ×Å£¬¾ßÓÐÁÙ´²ÆÕ¼°Ó¦ÓüÛÖµ¡£

¡¡¡¡±¾Ñо¿ÖжÔÉúÖ³Æ÷ðåÕîÕß½øÐÐÍâÍ¿ÓÃÒ©£¬·¢ÏÖ3dºóƤËð½áðèÇÒ½«ÍÑÂ䣬ûÓз¢ÉúË®Ö×ÎÊÌ⣬ҲûÓа̺ÛÁôÏ¡£¶Ô¼âÈñʪð໼ÕßÒÔðà¿Ë¾»É´ÌõµÄ·½Ê½µãÍ¿£¬2´Î/d, 2¡«3d½áðèÇÒ½«ÍÑÂ䣬ÎÞË®Ö×Îް̺ۣ¬ÖÎÁÆÆڼ仼ÕßÒ²ÎÞ²»ÊÊ¡£½á¹û±íʾ£ºÊµÑé×é96.97%µÄ×ÜÓÐЧÂʽ϶ÔÕÕ×é72.73%µÄ×ÜÓÐЧÂʸß(P<0.05)¡£ÊµÑé×é15.15%µÄ²»Á¼·´Ó¦·¢ÉúÂÊÓë¶ÔÕÕ×é9.09%µÄ·¢ÉúÂÊÏà±È²îÒì²»´ó(P>0.05)¡£Óɴ˿ɼû£¬ðà¿Ë¾»°²È«ÓÐЧ£¬¶ÔÓڳɹ¦ÖÎÓú»¼Õß¾ßÓлý¼«ÒâÒå¡£

¡¡¡¡¸ù¾ÝÉÏÊöÑо¿ËùµÃ£¬Ì½¾¿ðà¿Ë¾»Ò©Àí×÷ÓÃÏÔ×ÅÔ­Òò¾ßÌåÈçÏ£ºðà¿Ë¾»ÊôÓÚ´¿ÖÐÒ©ÖƼÁ£¬Ñ»µ¨×Ó¡¢É½¶¹¸ù¡¢»¢ÕÈ¡¢±ùƬ¡¢¿à²Î¡¢°Ü½´²ÝµÈΪÆäÖ÷Òª³É·Ö¡£Ñ»µ¨×Ó¿É·¢»ÓÇåÈÈ¡¢½â¶¾¡¢ÏûðàµÈЧ¹û¡£¡¶Ò½Ñ§ÖÔÖвÎÎ÷¼¡·ÖжÔÆ书ЧÓС°Ã·¶¾¼°»¨Áø¶¾ÁÜ¡±Ö®¼ÇÔØ£¬¡¶¿ÆѧµÄÃñ¼ä²ÝÒ©¡·Ôò±íʾÆä¾ßÓÐÖÎÁÆÍâ¶úµÀÈéÍ·×´Áö¡¢¼âÈñʪ´ÃµÈ¼ÇÔØ¡£µ±´úÑо¿±íʾ£¬ÔÚСÊóÊÔÑéÖУ¬²ÉÓÃÑ»µ¨×ÓÈÊË®¼åµÄ·½·¨ÖÎÁÆÆäÈéÍ·×´ÁöÄܹ»ÍƽøÍËÐÐÐԱ䣬·À·¶»µËÀ£¬Òò´Ë£¬ÊÔÑé±íʾ¸Ã·½·¨ÔÚÖÎÁÆÈéÍ·×´Áö¿ÉÉîÈëÑо¿¡£É½¶¹¸ùÓë°Ü½´²Ý¿É·¢»ÓÏûÖ×ֹʹµÄ¹¦Ð§£¬¾ßÓÐÇ¿²¡¶¾ÒÖÖÆÐÔ£¬Í¬Ê±Ò²¿ÉÒÖÖƶñÐÔÖ×Áö¡£Æѹ«Ó¢¿É·¢»ÓÇåÈÈ¡¢½â¶¾¡¢Éú¼¡µÈ¹¦Ð§£»»¢ÕÈ¿É·¢»Óìî·ç¡¢ÆÆñ±µÈ¹¦Ð§£¬ÔÚÖÎÁƶñÑ¢¼²·½Ãæ×÷ÓÃÏÔ×Å¡£ÁÙ´²Ñо¿»¹ÏÔʾðà¿Ë¾»¾ßÓп¹¾ú¡¢¿¹²¡¶¾µÄÓ¦ÓÃÓÅÊÆ£¬ÆäÄÚÒ¶ÓÍ¿É·¢»ÓÏûÖס¢Ö¹Í´µÈЧ¹û¡£ÉÏÊöÒ©ÎïºÏÀí´îÅ䣬¾ßÓÐÇåÈÈ¡¢½â¶¾¡¢ì¡¢ÏûÖס¢ìî׸µÈЭͬ×÷Óá£Òò´Ë½«ðà¿Ë¾»ÓÃÔÚÖÎÁƲ¡¶¾ÐÔƤ·ô²¡ÖУ¬Ð§¹ûÁ¼ºÃÓбØȻ֮ÊÆ¡£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡[1]ËïÓ±´ºðåÕîÐͲ¡¶¾ÐÔƤ·ô²¡ÁÙ´²ÓÃÒ©¹æÂÉ·ÖÎö[J]ÏÖ´úҽѧÓ뽡¿µÑо¿µç×ÓÔÓÖ¾, 2018,2(17):58;60.

¡¡¡¡[2]Áõ²©,°Ø±ùÑ©.Î÷ßäÎô¶¡ÖÎÁƲ¡¶¾ÐÔƤ·ô²¡µÄ»úÖƼ°ÁÙ´²Ó¦ÓÃ[J]ҽѧ×ÛÊö, 2018,24(7):1369 ~ 1373.


×÷Õßµ¥Î»£ººÓÄÏÊ¡å§ÑôÊа²ÑôµØÇøÒ½Ôº
Ô­Îijö´¦£º±ßéª.dzÎöðà¿Ë¾»ÖÎÁƲ¡¶¾ÐÔƤ·ô²¡µÄÖÎÁÆЧ¹û[J].ÊýÀíҽҩѧÔÓÖ¾,2021,34(11):1674-1675.
Ïà¹Ø±êÇ©£º
  • ±¨¾¯Æ½Ì¨
  • ÍøÂç¼à²ì
  • ±¸°¸ÐÅÏ¢
  • ¾Ù±¨ÖÐÐÄ
  • ´«²¥ÎÄÃ÷
  • ³ÏÐÅÍøÕ¾